CAR T Cell/Ibrutinib Combination May Improve CLL Response Rates
Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Hematology Leukemia & Lymphoma News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Conferences | Hematology | Leukemia | Lymphoma